/SHTDF

SHTDF Stock - Sinopharm Group Co. Ltd.

Q: What is the analyst price target for SHTDF?

Analyst price target information is not currently available for SHTDF.

Q: What is SHTDF's market cap?

Market capitalization information is not currently available for SHTDF.

Healthcare|Medical - Distribution|OTC

$2.47+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.72

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SHTDF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.59

52W High$2.53

52W Low$2.11

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$584.51B	$596.57B	$552.15B	$521.05B	$456.41B
Gross Profit	$44.26B	$48.51B	$47.43B	$44.05B	$40.32B
Gross Margin	7.6%	8.1%	8.6%	8.5%	8.8%
Operating Income	$16.19B	$20.21B	$20.60B	$19.71B	$17.76B
Net Income	$7.05B	$9.05B	$8.53B	$7.76B	$7.19B
Net Margin	1.2%	1.5%	1.5%	1.5%	1.6%
EPS	$2.26	$2.90	$2.73	$2.49	$2.31

Company Overview

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Visit Website

Earnings History & Surprises

SHTDF

Beat Rate

31%

Last 16 quarters

Avg Surprise

+20.6%

EPS vs Estimate

Beats / Misses

5/11

Last 12 quarters

Latest EPS

$1.11

Q3 2025

EPS Surprise History

Q1 23

-59.8%

$0.07vs$0.18

Q2 23

-1.6%

$0.18vs$0.18

Q1 24

-58.9%

$0.09vs$0.21

Q2 24

+5.4%

$0.22vs$0.21

Q2 24

No data

Q4 24

-14.0%

$0.16vs$0.19

Q1 25

-23.8%

$0.15vs$0.19

Q3 25

+719.8%

$1.11vs$0.14

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 23, 2026	—	—	—	—
Q3 2025	Aug 21, 2025	$0.14	$1.11	+719.8%	✓ BEAT
Q2 2025	Apr 25, 2025	—	—	—	—
Q1 2025	Mar 20, 2025	$0.19	$0.15	-23.8%	✗ MISS
Q4 2024	Oct 25, 2024	—	—	—	—
Q4 2024	Oct 25, 2024	$0.19	$0.16	-14.0%	✗ MISS
Q2 2024	Apr 26, 2024	—	$0.06	—	—
Q2 2024	Apr 26, 2024	$0.21	$0.22	+5.4%	✓ BEAT
Q1 2024	Mar 22, 2024	$0.21	$0.09	-58.9%	✗ MISS
Q2 2023	Jun 30, 2023	$0.18	$0.18	-1.6%	✗ MISS
Q1 2023	Mar 31, 2023	$0.18	$0.07	-59.8%	✗ MISS
Q4 2022	Dec 31, 2022	$0.22	$0.23	+0.8%	✓ BEAT
Q3 2022	Sep 30, 2022	$0.22	$0.10	-56.7%	✗ MISS
Q2 2022	Jun 30, 2022	$0.18	$0.18	-4.4%	✗ MISS
Q1 2022	Mar 31, 2022	$0.18	$0.07	-60.9%	✗ MISS
Q4 2021	Dec 31, 2021	$0.23	$0.21	-9.2%	✗ MISS
Q3 2021	Sep 30, 2021	$0.23	$0.11	-54.3%	✗ MISS
Q2 2021	Jun 30, 2021	$0.16	$0.18	+10.2%	✓ BEAT
Q1 2021	Mar 31, 2021	$0.16	$0.06	-63.1%	✗ MISS
Q4 2020	Dec 31, 2020	$0.21	$0.21	+0.5%	✓ BEAT

Frequently Asked Questions about SHTDF

What is SHTDF's current stock price?

Sinopharm Group Co. Ltd. (SHTDF) is currently trading at $2.47 per share. The stock has moved +0.00% today.

What is the analyst price target for SHTDF?

No analyst price targets are currently available for this stock.

What sector is Sinopharm Group Co. Ltd. in?

Sinopharm Group Co. Ltd. operates in the Healthcare sector, specifically within the Medical - Distribution industry. The company is traded on the OTC exchange.

What is SHTDF's market cap?

Sinopharm Group Co. Ltd. has a market capitalization of $7.71 billion, making it a mid-cap company.

Does SHTDF pay dividends?

No, Sinopharm Group Co. Ltd. does not currently pay a dividend to shareholders.